Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in Texas

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can—or should—prescribe weight loss medications like semaglutide (Wegovy, Ozempic) or phentermine, you’re not alone. The rise of GLP-1 receptor agonists has blurred traditional specialty lines, and many mental health providers are asking: Is this within my scope? What do state regulations say? Can I do this via telehealth? And does it even make financial sense?

The short answer: Yes, in most cases—but with important caveats. Psychiatrists (MDs/DOs) have full prescriptive authority nationwide for FDA-approved weight-loss medications. Psychiatric nurse practitioners face more variation: your ability to prescribe independently depends heavily on your state’s scope-of-practice laws, and in many states you’ll need a physician collaboration agreement.

This guide breaks down everything you need to know: the clinical rationale for psychiatrists entering this space, state-by-state prescribing rules, telehealth restrictions, reimbursement realities, and how to stay compliant while building a sustainable weight management service line.

Why Psychiatrists Are Prescribing GLP-1s (And Why It Makes Sense)

The Metabolic-Psychiatric Connection

Traditionally, weight management fell to primary care or endocrinology. But psychiatric patients face unique metabolic challenges: medication-induced weight gain from antipsychotics and mood stabilizers is common, and obesity itself worsens depression, anxiety, and self-esteem. Many psychiatrists now view treating obesity as inseparable from mental health care.

Dr. Elliott Lewis, a psychiatrist board-certified in obesity medicine, puts it plainly: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You’re already monitoring metabolic labs (glucose, lipids) for patients on psychiatric meds—prescribing a GLP-1 to address weight gain isn’t a stretch; it’s comprehensive care.

GLP-1s and Mental Health: What the Evidence Shows

Early concerns about GLP-1s causing depression or suicidal ideation have been debunked. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo—in fact, some trials showed slightly lower depressive symptoms in the GLP-1 groups. The FDA and EMA both reviewed the data and found no causal link to suicide risk.

There’s even emerging evidence of mental health benefits: improved mood scores independent of weight loss, reduced binge-eating impulses, and decreased substance cravings in some patients. The biological rationale is being studied (GLP-1s reduce inflammation, influence reward pathways), but practically: these meds appear safe and potentially helpful for psychiatric populations.

Scope of Practice: Competency, Not Tradition

The ‘is this in my scope?’ question comes down to competency. If you’ve gained the requisite knowledge—through CME, mentorship, or formal certification like the American Board of Obesity Medicine (which welcomes psychiatrists)—then prescribing GLP-1s is a reasonable extension of your practice. As one expert notes, ‘Scope is about competency rather than tradition.’

Many psychiatrists are pursuing dual certification in obesity medicine (approximately 60 hours of CME plus a board exam), which solidifies legitimacy and addresses any scope concerns head-on. You’re not abandoning psychiatry—you’re treating the whole patient, especially those struggling with both mental health issues and metabolic complications.

Key caveat: Collaborate appropriately. Communicate with the patient’s primary care provider, rule out endocrine causes of obesity (hypothyroidism, Cushing’s), and refer to specialists when needed. Document clearly that the intervention is part of comprehensive, evidence-based care.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Prescribing Authority: MDs vs. NPs

Psychiatrists (MDs/DOs): Full Authority, State-Specific Guardrails

As a physician, you can prescribe FDA-approved weight-loss medications in all 50 states. However, state medical boards impose clinical standards you must follow:

• Florida requires:

• Documented BMI ≥30 (or ≥27 with comorbidity) before prescribing

• A comprehensive physical exam (can be conducted via telehealth or delegated to an APRN/PA)

• Written informed consent and provision of the state’s ‘Weight-Loss Consumer Bill of Rights’

• Follow-up at least every 3 months while the patient is on medication

• PDMP check for controlled substances (like phentermine)

• New Jersey mandates:

• Complete history, physical exam, and labs before prescribing

• Assessment and treatment/stabilization of psychiatric conditions alongside weight management

• Nutritional counseling, exercise, and behavior modification—not just pills

• Virginia requires:

• Physical exam and documented diet/exercise plan

• Follow-up within 30 days of starting treatment, then at least monthly initially

• Mississippi has banned off-label GLP-1 prescribing for weight loss (you must use FDA-approved obesity drugs like Wegovy, not Ozempic off-label)

Bottom line: You have the authority, but check your state’s medical board rules and follow them to the letter. Missing a quarterly follow-up or prescribing to a patient with BMI 28 and no comorbidity could trigger board complaints.

PMHNPs: It Depends Entirely on Your State

Nurse practitioners face a patchwork of state laws. Here’s the breakdown:

Full Practice Authority (FPA) States (~24 states + DC):

• You can evaluate, diagnose, and prescribe independently after meeting state requirements
• Examples: Washington, Oregon, Colorado, Arizona, New Mexico, Iowa, Rhode Island, Maryland, DC
• Illinois: FPA available after ≥4,000 hours of practice and ≥250 hours of continuing education
• New York: Independent practice after 3,600 hours of supervised practice

Reduced/Restricted Practice States (~26 states):

• You need a physician collaboration or supervision agreement to prescribe

State-Specific Details:

Important: Even in FPA states, insurers and pharmacies sometimes require physician oversight for high-cost GLP-1 prescriptions—not because of law, but due to internal policies. Having a physician medical director relationship can smooth prior authorizations and credentialing.

Specialty Scope Considerations for PMHNPs

Your training focused on psychiatric assessment and psychotropics—not metabolic disorders. Can you still prescribe weight-loss medications?

Yes, with caveats:

• If you’re treating medication-induced weight gain in your existing psychiatric patients, prescribing metformin or a GLP-1 is arguably within holistic care
• If you want to run a standalone weight-loss practice, pursue additional training (obesity medicine CME, certification)
• State boards expect you to practice within your competency; document any supplemental education
• Many PMHNPs limit weight-loss prescribing to patients already under their psychiatric care, treating both conditions simultaneously

Practical tip: If your state requires collaboration, ensure your physician collaborator has obesity medicine experience and that your agreement explicitly authorizes weight management prescribing.

Telehealth Prescribing: Federal Waivers vs. State Restrictions

The Federal Landscape: DEA Extensions Through 2025

Pre-COVID, the Ryan Haight Act required an in-person exam before prescribing controlled substances. During the pandemic, the DEA waived this requirement. As of February 2026, federal waivers remain extended through December 31, 2025 (and likely beyond), allowing teleprescribing of controlled substances like phentermine without a prior in-person visit—if you meet the standard of care and state law permits it.

State Telehealth Restrictions: The Compliance Trap

Here’s where it gets tricky. Federal permission doesn’t override state prohibition. Some states explicitly ban or severely restrict controlled substance prescribing via telehealth:

Florida:

• Prohibits prescribing controlled substances via telehealth except for psychiatric treatment, inpatient/hospice care, or acute pain
• Weight loss is not an exception—you cannot prescribe phentermine via telehealth to Florida patients
• GLP-1s (like semaglutide) are not controlled substances, so they can be prescribed via telehealth if you follow Florida’s obesity treatment rules (BMI documentation, quarterly follow-ups, informed consent)

Alabama:

• Requires an initial in-person exam for any controlled substance prescription
• Effectively prohibits remote-start phentermine prescribing

Texas:

• Allows telehealth prescribing if standard of care is met
• No specific ban on controlled substances for weight loss via telehealth (federal waiver applies)
• Must check Texas PMP for controlled substances

California, New York, Pennsylvania, Illinois:

• Generally follow federal telehealth flexibility
• No additional state restrictions on controlled substance prescribing via telehealth beyond standard evaluation requirements

Key compliance points:

• Verify your state’s specific telehealth laws before prescribing
• For controlled substances, check your state PMP before every prescription
• Document a thorough video evaluation—async-only (questionnaire) models have led to license suspensions
• Some states require you to be physically located in that state when treating the patient; others don’t—check licensing requirements

Best practice: Use synchronous video visits for initial evaluations, document vital signs (even if patient-reported), order labs when appropriate, and schedule follow-ups per state requirements.

Reimbursement: Can You Actually Get Paid for This?

Insurance Coverage for GLP-1s Is Expanding Fast

A few years ago, weight-loss drugs were rarely covered. That’s changing:

Commercial Insurance:

• Most major insurers now cover FDA-approved obesity medications (Wegovy, Saxenda) with prior authorization
• Typical PA requirements: BMI ≥30 (or ≥27 with comorbidity), documentation of lifestyle modifications, comprehensive treatment plan
• Some plans impose 30-day supply limits initially to monitor tolerance and adherence (e.g., BCBS Texas started this in 2024)

Medicare/Medicaid:

• Historically excluded weight-loss drugs
• Game-changer: In November 2025, federal officials announced Medicare will begin covering GLP-1 weight-loss medications like Wegovy and Mounjaro
• Implementation expected by 2026, opening access to millions of seniors
• State Medicaid programs are following suit; coverage varies by state

How Visits Are Reimbursed

Billing Codes:

• Standard E/M codes (99202-99215 series) for outpatient visits
• Psychiatrists can bill initial psychiatric evaluations (90792, ~$200 Medicare reimbursement) or med management follow-ups (99213/99214, ~$75-$120)
• Obesity counseling codes (G0447 for 15-min face-to-face counseling) available but typically used by primary care

Telehealth Parity:

• California, New York, Illinois, Pennsylvania all have laws requiring commercial insurers to reimburse telehealth visits at the same rate as in-person
• Medicare continues paying telehealth at office visit rates through at least 2025 (likely extended)
• Most state Medicaid programs now cover telehealth with parity

MD vs. NP Reimbursement:

• Psychiatrists (MDs): 100% of physician fee schedule
• PMHNPs: 85% of physician rate under Medicare when billing under their own NPI
• Some states pay NPs at parity: Illinois Medicaid reimburses APRNs at 100% of physician rates
• Most commercial plans pay NPs 85-90% of MD rates (a few pay 100%)

Financial Reality:A psychiatrist doing a 15-20 minute medication management visit via telehealth can bill ~$100-150 (depending on complexity and region). If managing both psychiatric meds and a GLP-1, document both conditions and code accordingly. Higher volumes of shorter visits can make this financially sustainable, especially if insurance covers the expensive medications (making patients more likely to engage).

The Business Case: Platform vs. DIY Marketing

The Marketing Reality Check

Many providers assume they can acquire patients cheaply through DIY marketing. The reality is harder:

True Cost of Patient Acquisition:

• SEO: Takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo providers lack the expertise or patience.
• Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. Realistic cost per booked patient: $200-400+ when you factor in clicks that don’t convert, no-shows, and testing/optimization time.
• Directories (Psychology Today, Zocdoc): Monthly subscription fees plus you compete with hundreds of providers on the same page. Zocdoc charges per booking ($35-100+); total monthly costs add up quickly.
• Total DIY Reality: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient when you include all costs: agency/consultant fees, ad spend, staff time to qualify leads, no-show rates, months of SEO investment, and failed campaigns.

The Platform Advantage:

Instead of spending $3,000-5,000/month on marketing with uncertain results, platforms like Klarity Health use a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate EHR/platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

This is guaranteed ROI vs. gambling on marketing channels. For most providers—especially those starting out or scaling—a platform that handles patient acquisition removes the risk entirely.

FAQ: Weight-Loss Prescribing for Psychiatrists and PMHNPs

Q: Do I need special certification to prescribe GLP-1s?No legal requirement, but pursuing the American Board of Obesity Medicine certification strengthens your scope-of-practice justification and demonstrates competency. Many psychiatrists are doing this.

Q: Can I prescribe compounded semaglutide?Only if there’s an FDA-sanctioned shortage and the compounding pharmacy uses approved ingredients from registered facilities. Several states (Alabama, Mississippi) have warned against non-FDA-approved compounded versions. Stick with FDA-approved products when possible.

Q: What if my patient is already on psychiatric meds that cause weight gain?This is actually the ideal scenario for psychiatrists to prescribe GLP-1s—you’re managing the metabolic side effects of your own treatment. Document that the weight-loss medication is part of comprehensive psychiatric care.

Q: How do I handle prior authorizations for GLP-1s?Be prepared to document: BMI ≥30 (or ≥27 + comorbidity), previous weight-loss attempts (diet/exercise), comprehensive treatment plan, and why the medication is medically necessary. Many platforms and billing services can help with PA submissions.

Q: Can I prescribe phentermine via telehealth?Depends on your state. Federal waivers allow it, but states like Florida explicitly prohibit controlled substance prescribing via telehealth for weight loss. Texas, California, New York, Illinois, and Pennsylvania generally allow it under federal waivers. Always verify state law.

Q: What about liability—am I increasing my malpractice risk?If you practice within your competency, document appropriately, follow state guidelines, and collaborate with primary care when needed, your risk is manageable. Consider adding obesity medicine to your malpractice coverage if it becomes a significant part of your practice.

Q: Do I need a different DEA number to prescribe weight-loss controlled substances?No. Your existing DEA registration covers Schedule II-V drugs. Just ensure you’re compliant with state PMP requirements (checking the database before prescribing controlled substances).

Next Steps: Start Prescribing Weight-Loss Medications Compliantly

If you’re ready to add weight management to your practice:

1. Verify your state’s scope-of-practice rules (NPs: check if you need physician collaboration)
2. Review your state’s obesity prescribing guidelines and telehealth restrictions
3. Pursue additional training if needed (obesity medicine CME or certification)
4. Set up PMP access in every state where you’ll prescribe controlled substances
5. Develop clinical protocols that meet state requirements (BMI documentation, informed consent, follow-up schedules)
6. Decide on your patient acquisition strategy: DIY marketing (expensive, uncertain) or a platform like Klarity (guaranteed ROI, pre-qualified patients)

Interested in joining Klarity’s provider network?

We handle patient acquisition, telehealth infrastructure, and insurance credentialing—you focus on clinical care. Our providers see both psychiatric and weight-management patients, with built-in compliance support for multi-state practice.

Explore joining Klarity’s provider network →

Citations and Sources

1. MedicalDirector Co., ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025). Available at: https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co., ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (Updated 2025). Available at: https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co., ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (Updated 2025). Available at: https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code Rule 64B15-14.004, ‘Standards for Prescription of Obesity Drugs’ (Effective Aug 8, 2022, current through 2026). Available at: https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP, ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs,’ Mondaq (July 24, 2023). Available at: https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

6. RxAgent.co, ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (Dec 16, 2025). Available at: https://rxagent.co/blog/telehealth-compliance-trap

7. Susanne J. Phillips, ’36th Annual APRN Legislative Update: Improving Access to Healthcare Through Removing Practice Barriers,’ The Nurse Practitioner (January 2024). Available at: https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx

8. Elliott Lewis, MD, ‘Should Psychiatrists Prescribe GLP-1 Medications? An Evidence-Based Perspective,’ DrLewis.com (Jan 4, 2026). Available at: https://drlewis.com/glp-1-medications-psychiatry/

9. Elliott Lewis, MD, ‘GLP-1 Medications & Mental Health: Separating Facts from Myths,’ DrLewis.com (Nov 26, 2025). Available at: https://drlewis.com/glp-1-mental-health/

10. Axios, ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024). Available at: https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

11. Axios, ‘Trump announces Medicare coverage of weight-loss drugs’ (Nov 6, 2025). Available at: https://www.axios.com/2025/11/06/medicare-coverage-weight-loss-glp1-ozempic-trump

12. TheraThink, ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (2026). Available at: https://therathink.com/insurance-reimbursement-rates-for-psychiatrists/

13. Blue Cross Blue Shield of Texas, ‘Pharmacy Supply Limit for GLP-1 Obesity Medications’ (Oct 4, 2024). Available at: https://www.bcbstx.com/provider/education/education/news/2024/10-04-24-pharmacy-supply-limit-glp1-obesity

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting